AstraZeneca Higher Off Drug News And Upgrade

Also, before the open, the company reported progress with it Alzheimer's drug it is developing with Eli Lilly and Co LLY. AstraZeneca was also upgraded by Leerink Swann from Market Perform to Outperform.

After a higher open, it retreated only a penny to $26.70 before continuing its move higher. The issue was halted at 9:54 a.m. at $27.11. Upon the reopen, it reached $27.42 before falling back to its current level. That coincides with its November 17 high of $27.41.